Roche Receives the US FDA’s EUA for cobas SARS-CoV-2 and Influenza A/B Test

 Roche Receives the US FDA’s EUA for cobas SARS-CoV-2 and Influenza A/B Test

Roche Receives the US FDA’s EUA for cobas SARS-CoV-2 and Influenza A/B Test

Shots:

  • The US FDA has granted EUA for cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems to qualitatively detects and differentiate SARS-CoV-2, Influenza A and B in patients suspected of having respiratory viral infection consistent with COVID-19
  • The test is a multiplex RT-PCR assay intended to detect the virus in nasal/nasopharyngeal swab samples collected from the suspected individuals and is not intended for the detection of Influenza C virus
  • The test is available in markets accepting the CE mark. The COVID-19 and influenza infection can hardly be differentiated based on symptoms, HCPs can confidently provide the right diagnosis and best course of treatment for patients

Click here ­to­ read full press release/ article | Ref: Roche | Image: Medical Device Network

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post